Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lafleur, E. A.
Right arrow Articles by Kleinerman, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lafleur, E. A.
Right arrow Articles by Kleinerman, E. S.
Clinical Cancer Research Vol. 10, 8114-8119, December 1, 2004
© 2004 American Association for Cancer Research


Cancer Biology

Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells

Elizabeth A. Lafleur, Nadezhda V. Koshkina, John Stewart, Shu-Fang Jia, Laura L. Worth, Xiaoping Duan and Eugenie S. Kleinerman

Division of Pediatrics, Departments of Cancer Biology and Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Purpose: The process of metastasis requires the single tumor cell that seeds the metastatic clone to complete a complex series of steps. Identifying factors responsible for these steps is essential in developing and improving targeted therapy for metastasis. Resistance to receptor-mediated cell death, such as the Fas/Fas ligand pathway, is one mechanism commonly exploited by metastatic cell populations.

Experimental Design and Results: LM7, a subline of the SAOS human osteosarcoma cell line with low Fas expression, was selected for its high metastatic potential in an experimental nude mouse model. When transfected with the full-length Fas gene (LM7-Fas), these cells expressed higher levels of Fas than the parental LM7 cells or LM7-neo control-transfected cells. These cells were also more sensitive to Fas-induced cell death than controls. When injected intravenously into nude mice, the LM7-Fas cell line produced a significantly lower incidence of tumor nodules than control cell lines. Lung weight and tumor nodule size were also decreased in those mice injected with LM7-Fas. Levels of Fas were quantified in osteosarcoma lung nodules from 17 patients. Eight samples were Fas negative, whereas the remaining 9 were only weakly positive compared with normal human liver (positive control).

Conclusions: Our results demonstrate that altering Fas expression can impact the metastatic potential of osteosarcoma cells. We conclude that the increase of Fas on the surface of the LM7 osteosarcoma cells increased their sensitivity to Fas-induced cell death in the microenvironment of the lung, where Fas ligand is constitutively expressed. Thus, loss of Fas expression is one mechanism by which osteosarcoma cells may evade host resistance mechanisms in the lung, increasing metastatic potential. Fas may therefore be a new therapeutic target for osteosarcoma.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
P. Zhang, Y. Yang, P. A. Zweidler-McKay, and D. P.M. Hughes
Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis
Clin. Cancer Res., May 15, 2008; 14(10): 2962 - 2969.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Gordon, N. V. Koshkina, S.-F. Jia, C. Khanna, A. Mendoza, L. L. Worth, and E. S. Kleinerman
Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine
Clin. Cancer Res., August 1, 2007; 13(15): 4503 - 4510.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Orosco, O. Fromigue, C. Bazille, N. Entz-Werle, P. Levillain, P. J. Marie, and D. Modrowski
Syndecan-2 Affects the Basal and Chemotherapy-Induced Apoptosis in Osteosarcoma
Cancer Res., April 15, 2007; 67(8): 3708 - 3715.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.